
For patients over 65 and in good health, this is a study to determine if a stem cell transplant combined with maintenance therapy is a better option than non-transplant chemotherapy approaches and if it will provide older patients longer remission rates, more time without symptoms, toxicity and therapy, and an improved quality of life. Although several groups have confirmed the feasibility of autologous transplantation in myeloma patients over 65 years of age, the literature related to autotransplantation in this age group remains scarce. Most of the literature related to myeloma treatment in patients over 65 years of age involves non-transplant chemotherapy regimens, so this study will compare the autologous transplant with maintenance therapy compared to non-transplant treatment options for that age group. Study Phase: Phase II Location: University of Iowa For More Information contact Annick Tricot at annick-tricot@uiowa.edu

about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).
More on Life With Myeloma
Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:






.svg_7bb6fd32-1b73-4ca9-9a2f-8fd6fc59d528.png?alt=media)